Table 3. Median survival of patients in... | American Society of Hematology

Table 3.

Median survival of patients in early stage CLL based on IgV_H gene mutation and CD38 status

		IgV_H status			CD38 status
	Stage	Nonmutated, n	Mutated, n	Less than 30% positive, n	More than 30% positive, n
Damle et al⁷	Rai I or II	9	17	10	Not reached
Hamblin et al⁸	Binet A	7.9	24.4	—	—
Hamblin et al³⁸	Binet A	12.1	27	Not reached	25.8
Oscier et al³⁹	Binet A	10	25	*	*
Chevallier et al⁴⁵	Binet A	—	—	9.1	Not reached
Krober et al³⁵	Binet A	6.6	12.7	—	—
Ibrahim et al⁴⁶	Rai 0-II	—	—	3.7	Not reached
Ghia et al⁵⁰†	Rai 0	—	—	15.3	Not reached

		IgV_H status			CD38 status
	Stage	Nonmutated, n	Mutated, n	Less than 30% positive, n	More than 30% positive, n
Damle et al⁷	Rai I or II	9	17	10	Not reached
Hamblin et al⁸	Binet A	7.9	24.4	—	—
Hamblin et al³⁸	Binet A	12.1	27	Not reached	25.8
Oscier et al³⁹	Binet A	10	25	*	*
Chevallier et al⁴⁵	Binet A	—	—	9.1	Not reached
Krober et al³⁵	Binet A	6.6	12.7	—	—
Ibrahim et al⁴⁶	Rai 0-II	—	—	3.7	Not reached
Ghia et al⁵⁰†	Rai 0	—	—	15.3	Not reached

— indicates not evaluated.

Nonsignificant difference.

†

Study reported 3 categories of CD38 status: CD36^-, CD38⁺, and bimodal CD38 expression. Data presented for CD38^- and CD38⁺ groups are based on 30% cutoff. Discussed in “Mutational status and CD38.”

View Large

This Feature Is Available To Subscribers Only